SCHEMBL4031273

SCHEMBL4031273

COc1ccc(CC(=O)NNC(=S)NC(=O)c2ccccc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.71
KDM4E B2RXH2 3/20 0.71
MAPT P10636 2/20 0.71
CYP1A2 P05177 2/20 0.71
CYP2D6 P10635 2/20 0.71
CYP2C9 P11712 2/20 0.71
CYP2C19 P33261 2/20 0.71
CYP3A4 P08684 1/20 0.71
LMNA P02545 4/20 0.70
MEN1 O00255 2/20 0.70
KMT2A Q03164 2/20 0.70
PLAU P00749 1/20 0.68
ELANE P08246 1/20 0.68
TDP1 Q9NUW8 2/20 0.66
SMN1; SMN2 Q16637 4/20 0.63
HTT P42858 2/20 0.63
HSP90AA1 P07900 1/20 0.63
CRHBP P24387 1/20 0.63
CRHR2 Q13324 1/20 0.63
GAA P10253 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4025940 0.87 ALDH1A1 (0.76) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19
SCHEMBL4027858 0.83 KDM4E (0.74) ALDH1A1KDM4EMAPTCYP1A2CYP2C9
SCHEMBL4031975 0.82 ALDH1A1 (0.63) ALDH1A1KDM4EMAPTCYP1A2CYP2D6
SCHEMBL4033151 0.80 ALDH1A1 (0.61) ALDH1A1KDM4EMAPTCYP1A2CYP2D6
SCHEMBL9682481 0.78 PLAU (0.57) ALDH1A1KDM4EMAPTCYP1A2CYP2D6
SCHEMBL4029344 0.78 ALDH1A1 (0.86) ALDH1A1KDM4EMAPTCYP1A2CYP2C9
SCHEMBL21980985 0.76 HTT (0.86) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL14096442 0.76 EPHX1 (0.76) ALDH1A1MAPTCYP1A2CYP2C9CYP2C19
SCHEMBL4031988 0.75 ALDH1A1 (0.66) ALDH1A1KDM4EMAPTCYP1A2CYP2C9
SCHEMBL15145920 0.75 GAA (0.71) ALDH1A1KDM4ECYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379240-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2009-04-08 EP claimed
US-20060247280-A1 Compounds and methods SMITHKLINE BEECHAM CORPORATION 2006-11-02 US claimed
JP-2005506299-A 2005-03-03 JP claimed
EP-1379240-A1 COMPOUNDS AND METHODS SmithKline Beecham Corporation (US) 2004-01-14 EP claimed
WO-2002078696-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2002-10-10 WO claimed
EP-1379240-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2009-04-08 EP disclosed
US-20060247280-A1 Compounds and methods SMITHKLINE BEECHAM CORPORATION 2006-11-02 US disclosed
EP-1379240-A1 COMPOUNDS AND METHODS SmithKline Beecham Corporation (US) 2004-01-14 EP disclosed
WO-2002078696-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247280-A1 Compounds and methods METAP2, DNPEP, METAP1 ALDH1A1 1820/4885KDM4E 1184/4885MAPT 1962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.